Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2007Cited by 2.3k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Do‐Youn Oh et al.|New England Journal of Medicine|2023Cited by 530
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2005Cited by 344
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2023Cited by 163
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, Fangxin Hong et al.|JAMA Oncology|2020Cited by 106